A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
Crossref DOI link: https://doi.org/10.1007/s12325-020-01242-z
Published Online: 2020-02-11
Published Print: 2020-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Johansen, Pierre http://orcid.org/0000-0002-6287-7508
Sandberg, Anna
Capehorn, Matthew
Funding for this research was provided by:
Novo Nordisk
Text and Data Mining valid from 2020-02-11
Version of Record valid from 2020-02-11
Article History
Received: 10 December 2019
First Online: 11 February 2020